INNPF - Innocan Pharma files patent application for vaginal atrophy treatment

Innocan Pharma (OTCQB:INNPF), a company developing cannabis-based treatments, on Friday said it had filed a new patent application for a treatment for vaginal atrophy. Vaginal atrophy is a condition associated with loss of moisture, thinning, and inflammation of the vaginal walls, which can be due to decrease in estrogen levels in women. Israel-based micro-cap company INNPF said the patent application covers compositions which can be used to alleviate vaginal dryness and vaginal atrophy. With this new application, INNPF's intellectual property portfolio continues to expand.

For further details see:

Innocan Pharma files patent application for vaginal atrophy treatment